

Exploring peripheral neuropathy, symptoms of distress, hope and quality of life in Taiwanese patients with colorectal cancer after chemotherapy: A pilot study



Yichen Huang*1, Yajung Wang²

¹Department of Nursing, Taipei Veterans General Hospital; National Yang-Ming University, Taipei, Taiwan.

²Department of nursing, National Yang-Ming ₁ University, Taipei, Taiwan.

Outline of presentation

- Introduction
- Motivation
- Purpose
- Study framework
- Methods
- Statistical analyses
- Results
- Discussion

Introduction- CRC epidemiological

- Colorectal Cancer (CRC) is a major cause of morbidity and mortality.
- It accounts for > 9% of all cancer incidence.
- CRC is the 3rd most common cancer and the 4th most common cause of death (Siegel, Naishadham, & Jemal, 2012).
- Aggressive treatment which can increase neurological side effects, particularly in the peripheral nervous system (Mols, Beijers, Vreugdenhil, & Poll-Franse, 2014).

Introduction-Peripheral neuropathy

Symptoms of PN

Sensory symptoms


pain, tingling, burning, numbness, allodynia and hyperalgesia, typically in a "stocking-glove".

Motor functional impairment

weakness, gait and balance disturbance, difficulty with fine motor skills.

Autonomic Symptoms constipation, urinary retention, sexual dysfunction, and blood pressure alterations.

(Areti, Yerra, Naidu, & Kumar, 2014; Hile, Fitzgerald, & Studenski, 2010)





Introduction-Peripheral neuropathy

- PN incidence rates: 19% ∼85%.
- PN might last a short-time, or it can become a longterm problem (Fallon, 2013).
- The development of PN may require chemotherapy dose reduction or cessation(Wampler et al., 2007).

CHEMOTHERAPY AGENTS WHICH MAY CAUSE CIPN

- Cisplatin, carboplatin, and oxaliplatin
- Paclitaxel, docetaxel, and cabazitaxel
- Ixabepilone
- Vinblastine, vincristine, vinorelbine, and etoposide
- Thalidomide, lenalidomide, and pomalidomide
- Bortezomib and carfilzomib
- Eribulin



Introduction-PN & QoL

- Symptoms of PN usually mild and gradually get severe as treatment continues.
- PN may result in serious limitations in daily functioning, and might therefore have a negative impact on healthrelated quality of life (Tofthagen, Overcash, & Kip, 2011).

Introduction- Hope & QoL

- Hope is recognized as an important part of cancer treatment.
- Hope enables people to cope with difficult and stressful situations and suffering.
- Hope can be seen as a variable that positively contributes to the experience of quality of life (Jo, & Son. 2004;.

Motivation

- PN is not easy to be aware and negatively influences patient's physical, psychological, safety, and quality of life.
- Little western evidence demonstrates that PN influences patients' symptoms of distress, hope and quality of life (QOL).

Purpose

Explore phenomena of PN, symptoms of distress, hope and quality of life in Taiwanese colorectal population.

Study framework

Peripheral neuropathy **Demography** data: age, gender, marital status, level od **Quality of life** education **Health**related information: **Symptoms of distress** cancer stage, years since diagnosis, Hope comorbidities

Methods-Setting and Participants

The is a descriptive, correlational study design.

Inclusion criteria:

- >20 years old
- >1 cycle of chemotherapy
- Can listen, read or write Mandarin.

Exclusion criteria:

 Brain/spinal /spinal cord diseases, and second cancers

Methods- measuring tools

Distress-6 items

Likert 1-4(well of

Likert 0-4(better

quality of life)

of symptom)

12 items,

36 items,

hope)

Likert 0-10(severity

rion validity

validity

Chinese

0.82

Cronbach's α =0.85-0.93

Face/construct/content

Internal consistency a =

Internal consistency with

Concurrent validity

version 3, a = 0.90

Test retest reliability = 0.97

Methods- incasuling tools						
Variable s	Measurement tools	Content	Reliability and validity			
Severity grade of neuropat hy	Total Neuropathy Score-clinical version (TNSc)	7 items, 0-4(severity of PN)	Convergent/discriminant validity Inter-rater reliability Internal consistency = 0.80			
Symptom	MDASI-Taiwan	Severe-13 items	Construct/discriminant/crite			

s of

distress

Hope

life

Form

Quality of Functional

Severity: 0-130

Distress: 0-60

Herth Hope

Index (HHI)

Assessment for

Cancer

Treatment-

Colorectal

Ethical consideration

■ This study was reviewed and approved by the teaching hospital Institutional Review Board(104091-E).

Statistical analyses

- Descriptive analyses: mean, standard deviation, frequency, percentage
- Inferential analyses: Pearson's correlation and multiple linear regression

Results- Demography data

Table 1. Sample characteristics (N=40)

Variables	Mean	(SD)			Minimum	Ma	aximu	um
Age	60.1(9	.89)			38	79		
Variables		N	0/0	Variable	S		N	%
Gender				Education				
Male		22	55	Less than high school grad			24	60
Female		18	45	High school grad		7	17.5	
Domestic status				More than high school		9	22.5	
Married		29	72.5	2.5 Employment status				
Single		3	7.5	Full time			3	7.5
Divorced/ separated		4	10	9 Part time		2	5	
Bereft	Bereft		10 Retired			13	32.5	
				Unemp	loyed		22	55

Results- Demography data

Table 2. Cancer-related characteristics (N=40)

Variables	N	º/o	Variables	N	%
Years since diagnosis			Comorbidities		
<1 year	21	52.5	DM	1	2.5
1-3 years	13	32.5	Hypertension	5	12.5
>3 years	6	15	Heart disease	4	10
Stage			Osteoarthritis	0	0
I	2	5	Rheumatoid arthritis	0	0
П	1	2.5	CVA	0	0
Ш	20	50			
IV	17	42.5			16

Results- Demography data

Table 3. Means for neuropathy, hope, distress, QoL outcomes(N = 40)

Variables	N	%	Mean(SD)	Minimum	Maximum
Total Neuropathy Score(TNSc)>1	30	75	2.03(1.93)	1	8
MDASI-Taiwan Form- Severity			23.7(21.0)	0	83
MDASI-Taiwan Form- Distress			9.88(12.9)	0	54
Herth Hope Index (HHI)			37.8(4.09)	28	46
Functional Assessment for Cancer Treatment-Colorectal			93.9(18.9)	52	120 17

Results- Bivariate correlations

Table 4. Inter-item Correlations

	PNs	Symptom- severity	Symptom- distress	Норе	QoL
PNs	1	.543**	.623**	029	544**
Symptom -severity	.543**	1	.667**	093	667**
Symptom -distress	.623**	.667**	1	244	760**
Норе	029	093	244	1	.383*
QoL	544**	667**	760**	.383*	1

18

Results- Regression analyses

Table 5. Multiple regression analysis of factors associated with QoL

Variables	β	R ²	p
PNs	544	.296	.000
Symptom- Severity	667	.445	.000
Symptom- Distress	76	.578	.000
Норе	.383	.147	.015

Discussion

- This pilot study results suggested the prevalence of PN was relatively high and declined QOL.
- Severity and distress of symptoms were significantly and negatively impact QOL.
- Hope is a protect factor and positively impact QOL.

Discussion

- Nurses need to beware of this silent symptom.
- Early detect and in time manage PN.
- The findings of this pilot study suggested the patient of PN need more professional and individual care, more encouragement, and to improve their QoL.

THANKS FOR YOUR ATTENTION!